Alliance for Pandemic Preparedness

February 22, 2021

Decreased Neutralization of SARS-CoV-2 Global Variants by Therapeutic Anti-Spike Protein Monoclonal Antibodies

Category:

Keywords (Tags): , ,

[Pre-print, not peer-reviewed] A study testing the ability of therapeutic monoclonal antibodies REGN10933 and REGN10987 to neutralize SARS-CoV-2 variants B.1.1.7, B.1.351, mink cluster 5, and COH.20G/677H found that REGN10987 maintained most neutralization activity against viruses with B.1.1.7, B.1.351 and mink cluster 5 spike proteins. REGN10933 was not effective against B.1.351, which may be due to the K417N and E484K mutations in the receptor binding domain, while failure of REGN10933 to neutralize mink cluster 5 spike protein is due to the Y453F mutation. The combination of REGN10933 and REGN10987 was 9.1-fold less potent against B.1.351 and 16.2-fold less potent against mink cluster 5.

Tada et al. (Feb 19, 2021). Decreased Neutralization of SARS-CoV-2 Global Variants by Therapeutic Anti-Spike Protein Monoclonal Antibodies. Pre-print downloaded Feb 22 from https://doi.org/10.1101/2021.02.18.431897